Abstract
Chronic low back pain (CLBP) remains a leading
global cause of pain and disability, with
degenerative disc disease (DDD) historically
implicated as the predominant aetiology. Recent
research has introduced the concept of
vertebrogenic back pain (VLBP), a condition
where vertebral endplates contribute significantly
to CLBP. The Basi-vertebral nerve (BVN), which
innervates the vertebral endplates, has emerged as
a key target for therapeutic intervention in VLBP.
While BVN ablation (BVNA) has shown promise,
its integration into clinical practice remains in the
early stages. Supported by robust pre-clinical and
clinical evidence, the American Society of Pain
and Neuroscience (ASPN) has recognized the
need for evidence-based guidelines to guide
patient selection for BVNA. The ASPN’s
workgroup, which reviewed available literature,
concluded that BVNA offers Level A evidence,
confirming its substantial benefit in appropriately
selected individuals.
global cause of pain and disability, with
degenerative disc disease (DDD) historically
implicated as the predominant aetiology. Recent
research has introduced the concept of
vertebrogenic back pain (VLBP), a condition
where vertebral endplates contribute significantly
to CLBP. The Basi-vertebral nerve (BVN), which
innervates the vertebral endplates, has emerged as
a key target for therapeutic intervention in VLBP.
While BVN ablation (BVNA) has shown promise,
its integration into clinical practice remains in the
early stages. Supported by robust pre-clinical and
clinical evidence, the American Society of Pain
and Neuroscience (ASPN) has recognized the
need for evidence-based guidelines to guide
patient selection for BVNA. The ASPN’s
workgroup, which reviewed available literature,
concluded that BVNA offers Level A evidence,
confirming its substantial benefit in appropriately
selected individuals.